People with obesity and another health issue who got a weekly shot of semaglutide plus behavioral therapy lost about 17 kg on average after a year and a half — way more than those who got a placebo.
See the scientific wording
In adults with obesity and at least one comorbidity, once-weekly subcutaneous semaglutide at 2.4 mg combined with intensive behavioral therapy results in a mean body weight reduction of 16.8 kg after 68 weeks, which is significantly greater than the 6.2 kg reduction observed with placebo, demonstrating superior efficacy for weight loss in this population.
Unverified — no studies directly back this
We haven't found enough studies to verify this claim yet.
Score breakdown, mechanism chain, raw evidence, ideal studies needed
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
People with obesity and another health issue who got a weekly shot of semaglutide plus behavioral therapy lost about 17 kg on average after a year and a half — way more than those who got a placebo.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Semaglutide 2.4 mg + Behavioral Therapy vs Placebo for Weight Loss in Obese Adults with Comorbidities
Includes only double-blind, placebo-controlled RCTs with weight change as primary outcome, duration ≥68 weeks, and population defined as adults with obesity and ≥1 comorbidity
Double-Blind Semaglutide vs Placebo Trial for Weight Loss in Obese Adults with Comorbidities Over 68 Weeks
Randomized, double-blind, placebo-controlled trial with 1:1 allocation, primary outcome: mean weight change at 68 weeks, population: adults with BMI ≥30 and ≥1 comorbidity
Prospective Cohort Study of Semaglutide 2.4 mg and Behavioral Therapy on Weight Loss in Real-World Obese Patients with Comorbidities
Prospective observational cohort tracking weight change over 68 weeks in patients prescribed semaglutide 2.4 mg + behavioral therapy versus matched controls, adjusting for baseline comorbidities
Case-Control Study Comparing Weight Loss Outcomes in Patients Receiving Semaglutide 2.4 mg vs Non-Users with Obesity and Comorbidities
Retrospective comparison of patients who achieved ≥15 kg weight loss (cases) vs those who did not (controls), assessing prior exposure to semaglutide 2.4 mg + behavioral therapy over 68 weeks
Cross-Sectional Survey of Weight Loss in Adults with Obesity on Semaglutide 2.4 mg and Behavioral Therapy
Survey of patients currently on semaglutide 2.4 mg + behavioral therapy, measuring current weight and duration of treatment, comparing to self-reported baseline